Advertisement

Topics

AC Vaccine technology Company Profile

18:50 EDT 22nd September 2018 | BioPortfolio

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the animals were originally unresponsive to the protein. This work has been expanded by a number of researchers in various animal models. We now understand that a large number of T-cells react against the haptenized material and that a small percentage of the T-cells also react against the unmodified, natural material. We believe that tumor antigens, which are proteins, are similarly affected by haptenization.

Our AC Vaccine technology utilizes the patient’s tumor as the basis for a therapeutic vaccine. By extracting cancer cells from a tumor and then treating them with a hapten called dinitrophenyl (DNP), a vaccine is prepared that should be able to elicit a systemic immune response to the unmodified, native cancer cells. The induction of an immune response has been documented in a number of scientific publications. We believe that the best test of tumor immunity in patients is Delayed Type Hypersensitivity (DTH). DTH has long been used as a test for immunity to microbes, such as tuberculosis and is familiar to patients as the Tine test or PPD. DTH to cancer cells is tested in the same way, except that the patient’s cancer cells are the test agent. We have demonstrated that the DTH test to cancer cells is meaningful by showing a strong statistical relationship between the intensity of DTH and clinical outcomes, especially 5-year survival. We believe that the future acceptance of this relationship between DTH and clinical outcomes by the U.S. and European regulatory agencies is critical to the regulatory approval path for our AC Vaccine product candidates.

Location

4520 MAIN STSTE 930
KANSAS CITY
Missouri
64111
United States of America

Contact

Phone: 8169601333


News Articles [1272 Associated News Articles listed on BioPortfolio]

China police probe vaccine maker Changsheng Bio-technology: Xinhua

Chinese police are investigating vaccine maker Changsheng Bio-technology Co Ltd after the firm was found to have faked documents related to a rabies vaccine, the official Xinhua news agency reported o...

So you want to break into the Chinese vaccine market?

Last week, one of China’s largest vaccine makers, Changchun Changsheng Biotechnology, was exposed for selling and distributing hundreds of thousands...Read More... The post So you want to break into...

MIT team develops single-injection polymer vaccine for polio

Researchers at the Massachusetts Institute of Technology (MIT) in the US have developed a new single-injection vaccine that can carry...Read More... The post MIT team develops single-injection polymer...

Merck to partner with Jenner Institute to speed up vaccine availability

Science and technology company, Merck, has partnered with Oxford University’s Jenner Institute to develop cost-effective vaccine manufacturing processes, aimed at speeding up vaccine availability.

[CDC, Office of Women's Health, Health Matters for Women] Updated HPV Vaccine (Gardasil®) What You Need to Know

This updated information sheet answers eight questions: what is HPV, why get vaccinated, who should get this HPV vaccine and when, why should some people not get the vaccine or wait, what are the risk...

[Comment] A new step towards an HIV/AIDS vaccine

A preventive vaccine is an essential part of the strategy to eradicate the HIV pandemic.1 Although the search for an AIDS vaccine has led to many scientific advances, a vaccine remains out of reach. M...

Emergex receives £1m grant for universal flu vaccine

UK-based biotech Emergex Vaccines has received almost £1 million to accelerate its universal flu vaccine through preclinical trials. The British...Read More... The post Emergex receives £1m grant fo...

Pfizer starts Phase l/ll trial of RSV vaccine

Pfizer has commenced a Phase l/ll study of its unnamed respiratory syncytial virus (RSV) vaccine candidate in healthy adult subjects....Read More... The post Pfizer starts Phase l/ll trial of RSV vacc...

PubMed Articles [1547 Associated PubMed Articles listed on BioPortfolio]

Vaccine Technology VI: Innovative and integrated approaches in vaccine development.

Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania.

Monovalent rotavirus vaccine (RV1) was introduced in Tanzania in January 2013 under the Reach Every Child initiative, to be given at ages 6 and 10 weeks. We used the sentinel hospital rotavirus surv...

Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of non-vaccine serotypes among vaccinated infants and their mothers five years after PCV13 introduction in The Gambia.

The widespread use of pneumococcal conjugate vaccine (PCV) has brought about a dramatic decrease in pneumococci of vaccine serotypes (VT) but non-vaccine serotypes (NVT) have emerged. Robust data on V...

Influenza vaccine failure: Failure to protect or failure to understand?

I propose that influenza vaccine failure be defined as receipt of a properly stored and administered vaccine with the subsequent development of documented influenza. Several mechanisms of vaccine fail...

Practice Alert: ACIP vaccine update.

The Advisory Committee on Immunization Practices made relatively few new vaccine recommendations in 2017. One pertained to prevention of hepatitis B virus infection in infants born to HBV-infected mot...

Clinical Trials [4775 Associated Clinical Trials listed on BioPortfolio]

Immunity to Hepatitis B Vaccine

Infection and cancer is a major cause of death and morbidity, and may be preventable through vaccination. It is not fully understood at the molecular level why some people respond better t...

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on V

AMENDED 10/1/93: To evaluate the influence of prior immunization with an rgp120 vaccine on immune response to a subsequent immunization with a different strain of rgp120 (VEU 009X extensio...

Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects

In this study, subjects who were vaccinated with a meningococcal polysaccharide vaccine in a previous study (whose objectives & outcome measures are presented in a separate protocol postin...

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

GSK Biologicals is developing in partnership with the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative a candidate malaria vaccine for the routine immunizatio...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Companies [690 Associated Companies listed on BioPortfolio]

Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attract...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and ...

Variation Biotechnologies, Inc.

VBI is an emerging leader in the innovative formulation, delivery and development of vaccines. The Company’s powerful, proprietary technology platforms enable thermostable IM...

Pevion Biotech AG

Pevion Biotech AG is a fully independent Swiss vaccine company that develops innovative vaccines for unmet medical needs based on its clinically and commercially validated virosome technology. Its p...

Affinivax Inc.

Affinivax is advancing a next generation conjugate vaccine technology platform to enable the development of vaccines that provide the highest level of protection against challengi...

More Information about "AC Vaccine technology" on BioPortfolio

We have published hundreds of AC Vaccine technology news stories on BioPortfolio along with dozens of AC Vaccine technology Clinical Trials and PubMed Articles about AC Vaccine technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AC Vaccine technology Companies in our database. You can also find out about relevant AC Vaccine technology Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record